MedTrace Logo

Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation

NCT00033475 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-15

No results posted yet for this study

Summary

RATIONALE: Some types of lymphoproliferative disease are associated with Epstein-Barr virus. Combining reduced immunosuppressive therapy with donor white blood cells that have been treated in the laboratory to kill cells infected with Epstein-Barr virus may be an effective treatment for lymphoproliferative disease.

PURPOSE: Randomized phase III trial to compare the effectiveness of reducing immunosuppressive therapy with or without donor white blood cells in treating patients who have Epstein-Barr virus-associated lymphoproliferative disease after organ transplantation.

Conditions

  • Lymphoproliferative Disorder

Interventions

BIOLOGICAL

therapeutic allogeneic lymphocytes

Sponsors & Collaborators

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • Dorothy H. Crawford, MD · University of Edinburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
0 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-03-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00033475 on ClinicalTrials.gov